Skip to main content
Journal cover image

Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.

Publication ,  Journal Article
Untch, BR; Bonner, KP; Roggin, KK; Reidy-Lagunes, D; Klimstra, DS; Schattner, MA; Fong, Y; Allen, PJ; D'Angelica, MI; DeMatteo, RP; Kingham, TP ...
Published in: J Gastrointest Surg
March 2014

BACKGROUND: Duodenal neuroendocrine tumors are rare and few studies exist to guide surgical management. This study identifies factors associated with recurrence after resection. METHODS: A retrospective, single institution review was performed between 1983 and 2011 on patients with a pathologic diagnosis of duodenal neuroendocrine tumor. Tumor grade was assigned based on WHO 2010 criteria (Ki-67 and mitotic rate). RESULTS: Seventy-five patients were identified that underwent curative resection. This included 12 patients with endoscopic mucosal resection, 34 that had local resection, and 29 that underwent pancreaticoduodenectomy. Two-year and 5-year recurrence-free survival was 84 and 81%, respectively. There were 11 tumor recurrences (either local or distant), and four patients died of their disease (3/4 had high-grade lesions) with an overall median follow-up of 27 months. On univariate analysis, tumor size and tumor grade were identified as being associated with recurrence, but not intervention type, lymph node metastases, ampullary location, or margin status. CONCLUSIONS: Tumor grade and size are associated with recurrence-free survival in duodenal neuroendocrine tumors. When feasible, a less aggressive surgical approach to treat low-grade and low-stage duodenal NETs should be considered.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Gastrointest Surg

DOI

EISSN

1873-4626

Publication Date

March 2014

Volume

18

Issue

3

Start / End Page

457 / 462

Location

Netherlands

Related Subject Headings

  • Tumor Burden
  • Surgery
  • Retrospective Studies
  • Pancreaticoduodenectomy
  • Neuroendocrine Tumors
  • Neoplasm Recurrence, Local
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Lymphatic Metastasis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Untch, B. R., Bonner, K. P., Roggin, K. K., Reidy-Lagunes, D., Klimstra, D. S., Schattner, M. A., … Tang, L. H. (2014). Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg, 18(3), 457–462. https://doi.org/10.1007/s11605-014-2456-x
Untch, Brian R., Keisha P. Bonner, Kevin K. Roggin, Diane Reidy-Lagunes, David S. Klimstra, Mark A. Schattner, Yuman Fong, et al. “Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.J Gastrointest Surg 18, no. 3 (March 2014): 457–62. https://doi.org/10.1007/s11605-014-2456-x.
Untch BR, Bonner KP, Roggin KK, Reidy-Lagunes D, Klimstra DS, Schattner MA, et al. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg. 2014 Mar;18(3):457–62.
Untch, Brian R., et al. “Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors.J Gastrointest Surg, vol. 18, no. 3, Mar. 2014, pp. 457–62. Pubmed, doi:10.1007/s11605-014-2456-x.
Untch BR, Bonner KP, Roggin KK, Reidy-Lagunes D, Klimstra DS, Schattner MA, Fong Y, Allen PJ, D’Angelica MI, DeMatteo RP, Jarnagin WR, Kingham TP, Tang LH. Pathologic grade and tumor size are associated with recurrence-free survival in patients with duodenal neuroendocrine tumors. J Gastrointest Surg. 2014 Mar;18(3):457–462.
Journal cover image

Published In

J Gastrointest Surg

DOI

EISSN

1873-4626

Publication Date

March 2014

Volume

18

Issue

3

Start / End Page

457 / 462

Location

Netherlands

Related Subject Headings

  • Tumor Burden
  • Surgery
  • Retrospective Studies
  • Pancreaticoduodenectomy
  • Neuroendocrine Tumors
  • Neoplasm Recurrence, Local
  • Neoplasm Grading
  • Middle Aged
  • Male
  • Lymphatic Metastasis